NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that ZIO-101, a novel, proprietary organic arsenic, has been administered to the first patient in a phase II trial in blood and bone marrow cancers. Designed to confirm the anti-cancer activity of ZIO-101 seen in the phase I hematological trial, patients will receive intravenous ZIO-101 once daily for five consecutive days every four weeks for up to six cycles. The Company anticipates enrolling up to 40 patients at five U.S. clinical sites.
